Source: BioSpace

Gemphire Therapeutics: Privately-Held NeuroBo Enters Reverse-Merger Deal with Gemphire

Gemphire will enter into the reverse merger following a strategic review of its options.

Read full article »
Gemphire Therapeutics's Competitors | Gemphire Therapeutics's News | Gemphire Therapeutics's Financials
Stay up-to-date with the latest news on Gemphire Therapeutics
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Stephen Gullans's photo - President & CEO of Gemphire Therapeutics

President & CEO

Stephen Gullans

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Gemphire Therapeutics